Literature DB >> 167679

Binary ethylenimine as an inactivant for foot-and-mouth disease virus and its application for vaccine production.

H G Bahnemann.   

Abstract

Foot-and-mouth disease virus was inactivated with binary ethylenimine formed apart from or directly in the virus suspension by the cyclization of 2-bromoethylamine hydrobromide or 2-chloroethylamine hydrochloride under alkaline conditions. The inactivation rates with binary ethylenimine prepared apart from the virus suspension in dilute sodium hydroxide with either 2-bromoethylamine hydrobromide or 2-chlorethylamine hydrochloride were higher than with pure ethylenimine. When binary ethylenime was prepared directly in the virus suspension only 2-bromoethylamine hydrobromide gave acceptable inactivation rates. The reduced inactivation rates for binary ethylenimine directly prepared in the virus suspension are due to the different cyclization rates of 2-bromoethylamine hydrobromide and 2-chloroethylamine hydrochloride and to the interference of bicarbonate in the cyclization reaction. The complement fixing antigen of foot-and-mouth disease virus was not affected by binary ethylenimine inactivation. Vaccines prepared with foot-and-mouth disease virus inactivated by binary ethylenimine were comparable in their immunogenicity to vaccines prepared with ethylenimine or N-acetylethylenimine used as inactivants. Application of binary ethylenimine in the preparation of foot-and-mouth disease vaccines considerably reduces the potential danger associated with handling pure ethylenimine and other aziridines.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 167679     DOI: 10.1007/bf01315592

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  16 in total

1.  Application of agar-gel diffusion analysis to a study of the antigenic structure of inactivated vaccines prepared from the virus of foot-and-mouth disease.

Authors:  F BROWN; J CRICK
Journal:  J Immunol       Date:  1959-05       Impact factor: 5.422

2.  [THE OXAZOLIDONE REACTION OF 2-CHLOROETHYL-SUBSTITUTED SECONDARY AMINES].

Authors:  H ARNOLD; H BEKEL
Journal:  Arzneimittelforschung       Date:  1964-07

3.  Chemical reactions of the nitrogen mustard gases; the transformations of methyl-bis(beta-chloroethyl)amine in water.

Authors:  C GOLUMBIC; J S FRUTON; M BERGMANN
Journal:  J Org Chem       Date:  1946-09       Impact factor: 4.354

4.  Inactivation of influenza virus with sulfur and nitrogen mustards.

Authors:  H M ROSE; A GELLHORN
Journal:  Proc Soc Exp Biol Med       Date:  1947-05

5.  The sterilizing action of gaseous ethylene oxide; the effect of ethylene oxide and related compounds upon bacterial aerosols.

Authors:  S KAYE
Journal:  Am J Hyg       Date:  1949-11

6.  Derivatives of aziridine as inactivants for foot-and-mouth disease virus vaccines.

Authors:  R E Warrington; H R Cunliffe; H L Bachrach
Journal:  Am J Vet Res       Date:  1973-08       Impact factor: 1.156

7.  The inactivation of foot-and-mouth disease virus by ethylenimine and propylenimine.

Authors:  H G Bahnemann
Journal:  Zentralbl Veterinarmed B       Date:  1972-07

8.  [The inactivation of foot-and-mouth disease virus by ethylethyleneimine and the use of the inactivated virus in the preparation of vaccines].

Authors:  K Bauer
Journal:  Zentralbl Bakteriol Orig       Date:  1970-04

9.  Inactivation of foot-and-mouth disease virus with ethylenimine.

Authors:  H R Cunliffe
Journal:  Appl Microbiol       Date:  1973-11

10.  Inactivation of viruses and cells by mustard gas.

Authors:  R M HERRIOTT
Journal:  J Gen Physiol       Date:  1948-11       Impact factor: 4.086

View more
  40 in total

1.  Inactivation of viruses in serum with binary ethyleneimine.

Authors:  H G Bahnemann
Journal:  J Clin Microbiol       Date:  1976-02       Impact factor: 5.948

Review 2.  Foot-and-mouth disease.

Authors:  Marvin J Grubman; Barry Baxt
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

3.  Response to foot-and-mouth disease vaccines in newborn calves. Influence of age, colostral antibodies and adjuvants.

Authors:  A M Sadir; A A Schudel; O Laporte; M Braun; R A Margni
Journal:  Epidemiol Infect       Date:  1988-02       Impact factor: 2.451

4.  Capsid intermediates assembled in a foot-and-mouth disease virus genome RNA-programmed cell-free translation system and in infected cells.

Authors:  M J Grubman; D O Morgan; J Kendall; B Baxt
Journal:  J Virol       Date:  1985-10       Impact factor: 5.103

5.  Effect of two virus inactivation methods: electron beam irradiation and binary ethylenimine treatment on determination of reproductive hormones in equine plasma.

Authors:  N C Kyvsgaard; R Høier; I Brück; P Nansen
Journal:  Acta Vet Scand       Date:  1997       Impact factor: 1.695

6.  A large-scale evaluation of peptide vaccines against foot-and-mouth disease: lack of solid protection in cattle and isolation of escape mutants.

Authors:  O Taboga; C Tami; E Carrillo; J I Núñez; A Rodríguez; J C Saíz; E Blanco; M L Valero; X Roig; J A Camarero; D Andreu; M G Mateu; E Giralt; E Domingo; F Sobrino; E L Palma
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

7.  Comparison of pseudorabies virus inactivated by bromo-ethylene-imine, 60Co irradiation, and acridine dye in immune assay systems.

Authors:  I L Sun; D P Gustafson; G Scherba
Journal:  J Clin Microbiol       Date:  1978-11       Impact factor: 5.948

8.  Comparison of two different methods for inactivation of viruses in serum.

Authors:  T Preuss; S Kamstrup; N C Kyvsgaard; P Nansen; A Miller; J C Lei
Journal:  Clin Diagn Lab Immunol       Date:  1997-09

9.  Formaldehyde inactivation of foot-and-mouth disease virus. Conditions for the preparation of safe vaccine.

Authors:  S J Barteling; R Woortmeyer
Journal:  Arch Virol       Date:  1984       Impact factor: 2.574

10.  New vaccine design based on defective genomes that combines features of attenuated and inactivated vaccines.

Authors:  Teresa Rodríguez-Calvo; Samuel Ojosnegros; Marta Sanz-Ramos; Juan García-Arriaza; Cristina Escarmís; Esteban Domingo; Noemí Sevilla
Journal:  PLoS One       Date:  2010-04-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.